Navigation Links
Varian Medical Systems Schedules Webcast of Investor Meeting and Fiscal Year End Review at ASTRO in San Diego, November 2, 2010
Date:10/26/2010

PALO ALTO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) will hold a webcast of its investor event on Tuesday, November 2 at the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in San Diego.  The meeting and presentation will be webcast beginning at 7:30 a.m. pacific time.  To access the webcast, click on http://investors.varian.com/index.php?s=19&item=148.  The meeting will include a review of fiscal year 2010 and new products and technology being featured at the company's ASTRO exhibition.

Management presentations will focus on new technologies and products and growth initiatives within the company's Oncology Systems, X-Ray Products, and emerging businesses. Management will include: Varian Medical Systems' CEO and President Tim Guertin; Executive Vice President and Oncology Systems President Dow Wilson; Senior Vice President and CFO Elisha Finney; Senior Vice President and President X-Ray Products Robert Kluge; Vice President Emerging Businesses Lester Boeh; and Investor Relations Vice President Spencer Sias.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,200 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com.FOR INFORMATION CONTACT:Spencer Sias, (650) 424-5782Vice President, Corporate Communicationsand Investor Relationsspencer.sias@varian.com
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions ... Transformational M&A achieved through NPS and Dyax acquisitions and the ... M&A achieved through NPS and Dyax acquisitions and the announced ... with most robust pipeline in Shire , s ... most robust pipeline in Shire , s history ...
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... ALBANY, New York , February 11, 2016 ... Research announces the release of a new research report, titled ... Growth, Trends and Forecast, 2013 - 2019". According to the ... expand at a 4.40% CAGR from 2013 to 2019, growing ... bn by 2019. --> --> ...
Breaking Medicine Technology:
(Date:2/11/2016)... CA (PRWEB) , ... February 11, 2016 , ... ... extensive experience performing a wide range of cosmetic procedures. Along with performing procedures, ... the efficiency and results of many cosmetic procedures. One of the most common ...
(Date:2/11/2016)... ... February 11, 2016 , ... The Chartis Group, a ... five firms in the “2015/2016 Best in KLAS: Software and Services” report in ... a research and insights firm on a global mission to improve healthcare delivery ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, Inc. (AIS) ... A Case Study for Plans and Purchasers.” Executives from Intel Corp. and Providence ... on value-based health benefits program Connected Care, will discuss the challenges they faced ...
(Date:2/11/2016)... ... February 11, 2016 , ... Life is known for throwing ... 60 and older, who gather once a year to play softball to raise money ... the game, the more than 50 players who competed in this year’s softball tournament ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... communities with their ongoing community involvement program, introduces a new charity campaign to ... children, donations are now being accepted at https://donate.rmhc.org/ . , Ronald McDonald ...
Breaking Medicine News(10 mins):